AIDS and Behavior

, Volume 20, Issue 5, pp 1123–1131 | Cite as

The Effect of a Community-Based Exercise Program on Inflammation, Metabolic Risk, and Fitness Levels Among Persons Living with HIV/AIDS

  • Stacy E. Cutrono
  • John E. Lewis
  • Arlette Perry
  • Joseph Signorile
  • Eduard Tiozzo
  • Kevin A. Jacobs
Original Paper


The human immunodeficiency virus (HIV) pandemic remains a top national health priority. Chronic inflammation may be a critical component in the disease course of HIV as C-reactive protein (CRP) is elevated and associated with increased mortality. This study examined the effect of 3 months of combined aerobic and resistance exercise training among a diverse cohort of HIV-infected men and women. The fixed effect of time for CRP was found to be non-significant (F[1,57.3] = 1.7, p = 0.19). There was a significant fixed effect for time for upper body (F[1,51.6] = 18.1, p < 0.05) and lower body strength (F[1,48.0] = 15.7, p < 0.05) and significant declines in diastolic blood pressure (p = 0.002) and waist circumference (p = 0.027). Though levels of CRP were not impacted after 3 months training, participants demonstrated a significant increase in muscular strength as well as beneficial changes in metabolic risk factors. Future studies should focus on determining the optimal exercise intervention length and mode to reduce inflammation among individuals living with HIV.


Human immunodeficiency virus Aerobic exercise Resistance training C-reactive protein Inflammation Metabolic risk 



This material is based on work supported by AstraZeneca HealthCare Foundation’s Connections for Cardiovascular HealthSM (CCH) program. The CCH program funds charitable work, not research that addresses cardiovascular health issues within the United States and its territories. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and have not been reviewed for approval by the AstraZeneca HealthCare Foundation.


  1. 1.
    Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global AIDS Epidemic. 2013.Google Scholar
  2. 2.
    Centers for Disease Control and Prevention. HIV in the United States: at a glance. Accessed 15 Nov 2013.
  3. 3.
    Florida Health. Epidemiology of HIV Infection and trends in Florida reported through 2012. 2013.Google Scholar
  4. 4.
    Collaboration Antiretroviral Therapy Cohort. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96.CrossRefGoogle Scholar
  5. 5.
    Darbyshire J. Therapeutic interventions in HIV infection—a critical view. Trop Med Int Health. 2000;5(7):A26–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study AIDS. 1998;12(10):1195–201.PubMedGoogle Scholar
  7. 7.
    Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Tiozzo E, Jayaweera D, Rodriguez A, et al. Short-term combined exercise training improves the health of HIV-infected patients. J AIDS HIV Res. 2013;5(3):80–9.Google Scholar
  9. 9.
    Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med. 2011;5(2):171–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Leow MK, Addy CL, Mantzoros CS. Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88(5):1961–76.CrossRefPubMedGoogle Scholar
  11. 11.
    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.CrossRefPubMedGoogle Scholar
  12. 12.
    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–12.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010;5(6):498–503.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–95.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis. 2010;201(2):285–92.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637–46.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166(1):64–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009;200(6):973–83.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    O’Brien K, Nixon S, Tynan AM, Glazier R. Aerobic exercise interventions for adults living with HIV/AIDS. Cochrane Database Syst Rev. 2010. doi: 10.1002/14651858.CD001796.pub3.Google Scholar
  20. 20.
    O’Brien K, Tynan AM, Nixon S, Glazier RH. Effects of progressive resistive exercise in adults living with HIV/AIDS: systematic review and meta-analysis of randomized trials. AIDS Care. 2008;20(6):631–53.CrossRefPubMedGoogle Scholar
  21. 21.
    ACSM. ACSM’s guidelines for exercise testing and prescription. 9th ed. Baltimore: Wolters Kluwer|Lippincott Williams & Wilkins; 2009.Google Scholar
  22. 22.
    Arikawa AY, Thomas W, Schmitz KH, Kurzer MS. Sixteen weeks of exercise reduces C-reactive protein levels in young women. Med Sci Sports Exerc. 2011;43(6):1002–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology. 2002;13(5):561–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Kohut ML, McCann DA, Russell DW, et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun. 2006;20(3):201–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Campbell PT, Campbell KL, Wener MH, et al. A yearlong exercise intervention decreases CRP among obese postmenopausal women. Med Sci Sports Exerc. 2009;41(8):1533–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Kelley GA, Kelley KS. Effects of aerobic exercise on C-reactive protein, body composition, and maximum oxygen consumption in adults: a meta-analysis of randomized controlled trials. Metabolism. 2006;55(11):1500–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Kline GM, Porcari JP, Hintermeister R, et al. Estimation of VO2max from a one-mile track walk, gender, age, and body weight. Med Sci Sports Exerc. 1987;19(3):253–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Maruf FA, Akinpelu AO, Salako BL. Self-reported quality of life before and after aerobic exercise training in individuals with hypertension: a randomised-controlled trial. Appl Psychol Health Well Being. 2013;5(2):209–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Program National Cholesterol Education. (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.Google Scholar
  30. 30.
    United States Census Bureau. State and county QuickFacts. Accessed 18 May 2014.
  31. 31.
    Meredith K, Delaney J, Horgan M, Fisher E Jr, Fraser V. A survey of women with HIV about their expectations for care. AIDS Care. 1997;9(5):513–22.CrossRefPubMedGoogle Scholar
  32. 32.
    Kelly PJ, Cordell JR. Recruitment of women into research studies: a nursing perspective. Clin Nurse Spec. 1996;10(1):25–8.CrossRefPubMedGoogle Scholar
  33. 33.
    MacArthur RD, Levine SD, Birk TJ. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med Sci Sports Exerc. 1993;25(6):684–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Neidig JL, Smith BA, Brashers DE. Aerobic exercise training for depressive symptom management in adults living with HIV infection. J Assoc Nurses AIDS Care. 2003;14(2):30–40.CrossRefPubMedGoogle Scholar
  35. 35.
    Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005;165(18):2063–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Smith BA, Neidig JL, Nickel JT, Mitchell GL, Para MF, Fass RJ. Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS. 2001;15(6):693–701.CrossRefPubMedGoogle Scholar
  37. 37.
    Lindegaard B, Hansen T, Hvid T, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab. 2008;93(10):3860–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Gomes Neto M, Ogalha C, Andrade AM, Brites C. A systematic review of effects of concurrent strength and endurance training on the health-related quality of life and cardiopulmonary status in patients with HIV/AIDS. Biomed Res Int. 2013;2013:319524.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hand GA, Lyerly GW, Jaggers JR, Dudgeon WD. Impact of aerobic and resistance exercise on the health of HIV-infected persons. Am J Lifestyle Med. 2009;3(6):489–99.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–35.CrossRefGoogle Scholar
  41. 41.
    Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6):1056–74.CrossRefPubMedGoogle Scholar
  42. 42.
    Borato DC, Parabocz GC, Ribas SR, et al. Changes of metabolic and inflammatory markers in HIV infection: glucose, lipids, serum Hs-CRP and myeloperoxidase. Metabolism. 2012;61(10):1353–60.CrossRefPubMedGoogle Scholar
  43. 43.
    Tiozzo E, Konefal J, Adwan S, et al. A cross-sectional assessment of metabolic syndrome in HIV-infected people of low socio-economic status receiving antiretroviral therapy. Diabetol Metab Syndr. 2015;7:15. doi: 10.1186/s13098-015-0008-5.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43(4):458–66.CrossRefPubMedGoogle Scholar
  45. 45.
    Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21(18):2445–53.CrossRefPubMedGoogle Scholar
  46. 46.
    Palacios R, Santos J, Gonzalez M, Ruiz J, Marquez M. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS. 2007;18(3):184–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24(3):427–35.CrossRefPubMedGoogle Scholar
  48. 48.
    Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol. 2007;47(12):1570–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Stacy E. Cutrono
    • 1
    • 2
  • John E. Lewis
    • 3
  • Arlette Perry
    • 1
  • Joseph Signorile
    • 1
  • Eduard Tiozzo
    • 3
  • Kevin A. Jacobs
    • 1
  1. 1.Department of Kinesiology and Sports Sciences, School of Education and Human DevelopmentUniversity of MiamiCoral GablesUSA
  2. 2.Sylvester Comprehensive CancerUniversity of Miami, Miller School of MedicineMiamiUSA
  3. 3.Department of Psychiatry & Behavioral SciencesUniversity of Miami, Miller School of MedicineMiamiUSA

Personalised recommendations